Claim 20% Off Global Market Reports With Code ONLINE20 – Insights on Tariff Effects, Global Trade, and Industry Disruptors

What Is The Predicted Market Size Of The Intravenous Immunoglobulin Industry By 2029?

The market for intravenous immunoglobulin has seen substantial growth over recent years. The market value is expected to increase from $14.66 billion in 2024 to $15.57 billion in 2025, with a compound annual growth rate (CAGR) of 6.2%. The previous growth can be credited to its use in treating primary immunodeficiency disorders, handling neurological conditions, increased elderly population, advancements in techniques for plasma fractionation, expansion in neurological indications, and its role in treating infectious diseases and pediatric immunodeficiency.

The market size for intravenous immunoglobulin is poised to witness robust expansion in the coming years, projected to reach $21.53 billion by 2029 with a CAGR of 8.4%. This prospective growth during the forecast period can be ascribed to a surge in autoimmune disorders, intensified immunology research, escalating healthcare costs, a rise in cancer rates, novel immunoglobulin products, and personalized medicine approaches. The forecast period also anticipates key trends such as treatment for primary immunodeficiency disorders (PIDD), swift technological evolution, strategic collaborations and alliances, enhancements in manufacturing methodologies, neurological applications, use in the field of hematology, and advancements in immunotherapy.

Get A Free Sample Of The Report:

https://www.thebusinessresearchcompany.com/sample.aspx?id=8538&type=smp

What Growth-Enabling Forces Are Impacting The Intravenous Immunoglobulin Market?

The advancing age of the population is predicted to propel the intravenous immunoglobulin market forward. The term ‘geriatric population’ pertains to those who are 65 years of age or older. As age increases, the immune system does not function as effectively and there is a deficiency in antibodies. Consequently, they require immunoglobulins to supply them with the necessary antibodies. This raises the demand for intravenous immunoglobulins and propels the intravenous immunoglobulin market. For example, in January 2024, the Population Reference Bureau, a Nonprofit organization based in Kenya, projected that the American population aged 65 and older will swell from 58 million in 2022 to 82 million by 2050, marking a 47% increase. The proportion of this age group within the overall population is also anticipated to climb from 17% to 23% over the same stretch of time. Therefore, the escalating older population will fuel the progress of the intravenous immunoglobulin market.

Which Segmentation Factors Are Critical In The Intravenous Immunoglobulin Market Analysis?

The intravenous immunoglobulin market covered in this report is segmented –

1) By Type: IgG (Immunoglobulin G), IgM (Immunoglobulin M), IgA (Immunoglobulin A), IgE (Immunoglobulin E), IgD (Immunoglobulin D)

2) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Other Distribution Channels

3) By Application: Hypogammaglobulinemia, Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), Primary Immunodeficiency Diseases, Myasthenia Gravis, Multifocal Motor Neuropathy, Other Applications

4) By End-User: Hospitals, Clinics, Home Care

Subsegments:

1) By Immunoglobulin G (IgG): Normal IgG, Specific IgG

2) By Immunoglobulin M (IgM): Normal IgM, Specific IgM

3) By Immunoglobulin A (IgA): Normal IgA, Specific IgA

4) By Immunoglobulin E (IgE): Normal IgE, Specific IgE

5) By Immunoglobulin D (IgD): Normal IgD, Specific IgD

What Are The Dominant Trends Currently Seen In The Intravenous Immunoglobulin Market?

A significant trend growing in prominence within the intravenous immunoglobulin market is product innovation. Numerous prominent businesses are concentrating on creating novel products such as liquid immune globulin formulations for the treatment of immunodeficiency diseases, in a bid to maintain their market position. For instance, GC Pharma, a pharmaceutical firm based in South Korea, rolled out its FDA-approved product, Alyglo, in December 2023. This product is a sterile, ready-to-use liquid formulation with a composition of 10% immunoglobulin G (IgG), which equates to 100 mg/mL of protein, and at least 96% of this is human IgG procured from combined human plasma. Alyglo is primarily used for treating primary humoral immunodeficiency (PI) in adults who are 17 years and older. This includes aspects like congenital agammaglobulinemia, common variable immunodeficiency (CVID), Wiskott-Aldrich syndrome, and severe combined immunodeficiency (SCID).

Which Players Are Shaping The Competitive Landscape Of The Intravenous Immunoglobulin Market?

Major companies operating in the intravenous immunoglobulin market are Bio Products Laboratory Limited, Biotest AG, China Biologic Products Holdings Inc., CSL Behring, Grifols S.A., Kedrion SpA, Shanghai RAAS Blood Products Co. Ltd., Octapharma AG, Takeda Pharmaceutical Company Limited, Baxter International Inc., LFB Biotechnologies SAS, BDI Pharma Inc., Hualan Biological Engineering Inc., ADMA Biologics Inc., Bharat Serums and Vaccines Limited, Sanquin Plasma Products B.V., Prothya Biosolutions B.V., Sichuan Yuanda Shuyang Pharmaceutical Co. Ltd., Pfizer Inc., Kedrion Biopharma, Intas Pharmaceuticals, Octapharma Pharmazeutika Produktionsges.m.b.H., GC Pharma, Grifols Biologicals Inc., Kamada Ltd., LFB USA, Octapharma Plasma Inc., Panacea Biotec Ltd.

Access The Complete Report Here:

https://www.thebusinessresearchcompany.com/report/intravenous-immunoglobulin-global-market-report

Which Region Is Likely To Register The Fastest Growth In The Intravenous Immunoglobulin Market?

North America was the largest region in the intravenous immunoglobulin market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the intravenous immunoglobulin market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Customize Your Report Here:

https://www.thebusinessresearchcompany.com/customise?id=8538&type=smp

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model